Business Description
Aptevo Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03835L1089
Description
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.61 | |||||
| Equity-to-Asset | 0.29 | |||||
| Debt-to-Equity | 1.09 | |||||
| Debt-to-EBITDA | -0.2 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 35.3 | |||||
| 3-Year EPS without NRI Growth Rate | 35.2 | |||||
| 3-Year FCF Growth Rate | 53.6 | |||||
| 3-Year Book Growth Rate | -44.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 66.53 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 42.26 | |||||
| 9-Day RSI | 45.35 | |||||
| 14-Day RSI | 47.53 | |||||
| 3-1 Month Momentum % | -22.08 | |||||
| 6-1 Month Momentum % | -66.67 | |||||
| 12-1 Month Momentum % | -96.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | |||||
| Quick Ratio | 1.7 | |||||
| Cash Ratio | 1.32 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -64 | |||||
| Shareholder Yield % | -165.48 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -282.9 | |||||
| ROA % | -119 | |||||
| ROIC % | -303.78 | |||||
| 3-Year ROIIC % | 22.24 | |||||
| ROC (Joel Greenblatt) % | -442.36 | |||||
| ROCE % | -180.89 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.96 | |||||
| Price-to-Tangible-Book | 0.96 | |||||
| EV-to-EBIT | -0.06 | |||||
| EV-to-EBITDA | -0.06 | |||||
| EV-to-Forward-Revenue | 0.07 | |||||
| EV-to-FCF | -0.08 | |||||
| Earnings Yield (Greenblatt) % | -1666.67 | |||||
| FCF Yield % | -505.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:APVO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aptevo Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3598.314 | ||
| Beta | 1.23 | ||
| 3-Year Sharpe Ratio | -1.95 | ||
| 3-Year Sortino Ratio | -1.84 | ||
| Volatility % | 131.84 | ||
| 14-Day RSI | 47.53 | ||
| 14-Day ATR ($) | 1.55127 | ||
| 20-Day SMA ($) | 9.85672 | ||
| 12-1 Month Momentum % | -96.55 | ||
| 52-Week Range ($) | 5.106 - 399.6 | ||
| Shares Outstanding (Mil) | 0.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aptevo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aptevo Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Aptevo Therapeutics Inc Frequently Asked Questions
What is Aptevo Therapeutics Inc(APVO)'s stock price today?
The current price of APVO is $9.20. The 52 week high of APVO is $399.60 and 52 week low is $5.11.
When is next earnings date of Aptevo Therapeutics Inc(APVO)?
The next earnings date of Aptevo Therapeutics Inc(APVO) is 2025-03-05 Est..
Does Aptevo Therapeutics Inc(APVO) pay dividends? If so, how much?
Aptevo Therapeutics Inc(APVO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers